LONDON, March 31, 2010 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO) announced a strategic partnership with endpoint. With this investment, Chiltern becomes a minority shareholder in the company established in April 2009.
Glenn Kerkhof, Chiltern CEO, stated, Chiltern's decision to invest in endpoint is representative of our commitment to seek collaborations which connect Chiltern and our clients with leading edge solutions as well as our belief in the technology that endpoint has developed. Jon Dole and Tom O'Connell are bringing a new level of energy and innovation to Interactive Response Technology services to provide solutions which are meeting clients' needs for flexibility, efficiency and savings while ensuring the highest possible quality. We believe that endpoint has listened - and is responding - to the industry's needs for IVR/IWR solutions and we look forward to introducing endpoint to our customers as a Chiltern qualified vendor that will meet their needs and exceed their expectations in a manner that mirrors Chiltern's commitment to the same.
Jonathan Dole, endpoint CEO, stated, Chiltern's enthusiasm and investment affirms our confidence in the solutions we are bringing to the marketplace. At endpoint, we are delighting our clients with approaches that are exceeding their needs. Our experience in the IVR/IWR space, coupled with a fresh and logical approach to systems development, is giving our customers the agility they need in a constantly changing RD environment. We are very pleased to be working closely with Chiltern to identify and act on opportunities for synergies across our two organizations.
PULSE, endpoint's fully configurable system that allows users to design and deploy clinical trial IRT systems at a fraction of the time and cost of other providers, was launched in January of this year. Providing both high speed of deployment and flawless quality, PULSE simultaneously designs systems that can be accessed via the phone, web, or mobile device.
Company profiles
About Chiltern:
Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries, has 24 offices and legal entities within 20 countries, resources in 37 countries and employs nearly 1,400 people globally. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information is available at http://www.chiltern.com.
About endpoint:
endpoint is an innovative company dedicated to the development of the leading Interactive Response Technology (IVR/IWR) platforms for the life sciences industry. endpoint's founding team members have been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma and biotech companies for domestic and global studies with experience across a broad range of therapeutic areas and global implementations. http://www.endpointclinical.com
For More Information Contact: Natalie Chong Sue Ojanen Marketing Director Marketing Associate Chiltern International Ltd. Chiltern International Inc. 171 Bath Road 1241 Volunteer Parkway Slough Suite 950 Berkshire SL1 4AA Bristol, TN 37620 UNITED KINGDOM USA Tel: +44-(0)-1753-512-000 Tel: +1-423-968-9533 Fax: +44-(0)-1753-511-116 Fax: +1-423-968-3567 Email: natalie.chong@chiltern.com Email: sue.ojanen@chiltern.com endpoint Contact : Rich Mullikin, APR Marketing Director endpoint 690 Texas Street San Francisco, CA 94107 USA Tel: +1-925-779-9115 Email: rmullikin@endpointclinical.com
SOURCE: Chiltern
CONTACT: Natalie Chong, Marketing Director, +44-(0)-1753-512-000, Fax,+44-(0)-1753-511-116, natalie.chong@chiltern.com, or Sue Ojanen MarketingAssociate, +1-423-968-9533, Fax, +1-423-968-3567, sue.ojanen@chiltern.com,both of Chiltern International Ltd.; or Rich Mullikin, APR, MarketingDirector of endpoint, +1-925-779-9115, rmullikin@endpointclinical.com
Comments